Verona Pharma Share Discussion Threads

[fatgreek] 08/11/2015 23:44

Verona completes key asthma studyBen JaglomAIM-quoted pharma minnow Verona Pharma (VRP) has completed its Phase II study for asthma treatment RPL554.The company, which specialises in treatments for conditions such as asthma, fever and other chronic respiratory diseases remarked it had successfully completed a study to 'test the duration of bronchodilator (a bronchodilator is a substance that helps increase the flow of air to the lung) action with repeated does of its lead drug' in patients with a mild form of asthma.The trial took place in Leiden in The Netherlands at the Centre for Human Drug Research (CHDR) treating 12 patients with mild asthma with daily doses for a period of 6 days. The patients were tested every day but the major observations concerning bronchodilation were on days 1, 3 and 6 when measurements continued for 6 hours. Verona enthused that the trial 'successfully demonstrated that RPL554 had sustained bronchodilator actions throughout the treatment period.'

[timbo003] 07/11/2015 05:29

>>>>Thanks Fatgeek

Link to presentation now in the header

[fatgreek] 06/11/2015 22:43

https://t.co/qGNV2O3oiLGood presentation on VRP

[fatgreek] 06/11/2015 15:38

LONDON (Alliance News) - Verona Pharma PLC Thursday said it has completed patient enrolment for the dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease.The drug development company said RPL554 is a novel inhaled PDE3/PDE4 inhibitor with anti-inflammatory as well as bronchodilatory properties, currently in development as a nebulised treatment for acute exacerbations in COPD patients in a hospital or home-care setting.Phase IIa results from a prior study using nebulised RPL554 alone in stable COPD patients with moderate severity of disease, showed that in addition to good tolerability and safety profile,RPL554 caused a pronounced improvement in lung function, suggesting the drug produced a clinically meaningful bronchodilator effect, it added.Headline data is expected in the first quarter of 2016 for the asthma study and in the second quarter of 2016 for the COPD study."We are very pleased to have completed recruitment in both of these studies ahead of our plan. We believe the results will continue to build on the positive data recently announced from our Phase I/IIa study, which demonstrated that the new commercially scalable, suspension formulation of RPL554 is well tolerated and that the extent of the bronchodilation exceeded that seen in earlier studies with the prior formulation. We believe RPL554 has the potential to become an important new treatment option for both COPD and asthma patients and look forward to reporting headline data from both studies in the first half of next year," Chief Executive Jan-Anders Karlsson said in a statement.Back to Alliance News

[fatgreek] 06/11/2015 15:22

N+1 Singer reiterated their corporate rating on shares ofVerona Pharma Plc (LON:VRP) in a research note issued to investors on Thursday, Market Beat Ratings reports.

[fatgreek] 06/11/2015 14:46

And there's my trade showing.....This could easily fly imo back up to 5p

[fatgreek] 06/11/2015 14:44

Just bought 229k

[bangbang1] 05/11/2015 09:56

Baron - BANG ON WITH THAT COMMENT

[mortimer7] 05/11/2015 09:35

Baron Day Trading ‏@barondaytrading 2 hours ago
#VRP Verona Pharma - a victim of profit taking lately despite the co only make strides forward. Continued progress

[aimshares] 04/11/2015 21:30

FEV1 increase ranged from 199 ml to 257 ml versus placebo. That's a 25% increase

[aimshares] 04/11/2015 20:49

The very important bit Page 13§? RPL554 caused pronounced improvement in lung funcTon§? Mean peak FEV1 increase ranged from 199 ml to 257 ml versus placebo

[bewise2] 04/11/2015 19:36

www.veronapharma.com/joomla/images/VRP_Corp_BIO-Europe_presentation_3_Nov_2015.compressed.pdf

[thebossman] 03/11/2015 09:54

Something really stinks about the Aim market and who runs it...

[halfpenny] 30/10/2015 17:58

So how much lower will we see 2.3 p ..?

[halfpenny] 30/10/2015 14:37

VRP...Wot a mess, try OXP as its well funded by WPCT woodford......he paid 10 million for shares recently...and news comming out soon....

Try OXP and have an early XMas....

[haff1] 30/10/2015 13:08

Interesting...

[vasilis] 30/10/2015 12:53

I've just come across this on British Bulls which re-iterates followers maintaining a 'short' position -

I wonder if this is the real story behind the recent downward movement in the SP?

[vasilis] 30/10/2015 12:39

haff1

I do sympathise with all fellow long term holders.

However, whilst there was more hype than substance under previous management in my view - particularly with regard to VRP700 - we're now in the position whereby all resources are going into our only drug undergoing trials, and by the end of next year AT THE VERY LATEST that 'light at the end of the tunnel' will either be 'the promised land' or the main beam of an on-coming locomotive. It's as simple as that in my view if you take into account the potential future outcomes of the current trials. I cannot see it any other way but that 2016 is either make or break for VRP - regardless of what the share price is today - or at what price the anticipated placing is made.

[haff1] 30/10/2015 12:05

True Vasilis but its been a long haul....I like Aim Shares have been here for years...I first brought in Auguat 09!

[vasilis] 30/10/2015 09:05

Bearing in mind that all is going as planned with the trials, I agree that the movement of the share price over the last few days seems to strongly suggest that the the reason is the anticipated share placing to raise the necessary moollah. It could also be a major holder bailing out - just a possibility, though I think a placing more likely.

If this share price action is in relation to a future placing then it's not unusual whilst the broker does the usual 'book building' exercise getting commitments from investors - and things can get a bit 'leaky' shall we say. It's not supposed to happen but......If this is correct, then the way the share price has moved suggests that the price investors are prepared to pay is c.2.5p.

Whilst if the anticipated placing happens at this price then it is of course disappointing for us long term holders, in the end it's the trial results which will count for everything and there's quite a bit of news expected over the next few months - which is probably why investors want to buy in now at a low price rather than when anticipated future good news from trials pushes the price higher. We'll know soon enough what's going on here one way or another as and when the anticipated RNS duly arrives in respect of a seller or a placing.

[aimshares] 30/10/2015 09:03

haff been in vrp over 6 years I have no hair left mate.